Kidney Transplant- Selection of Recipients, Donors and the Preparations




台中慈濟醫院 陳至正

- Cause of Kidney Disease
- Recurrence risk in primary focal segmental glomerulosclerosis, hemolytic-uremic syndrome, membranoproliferative glomerulonephritis, and primary oxalosis
- HTN and DM are the most common causes of renal failure in adults need to be controlled after RTx for better outcome
- History of childhood enuresis or urinary tract infections (UTIs) should be ware of congenital urinary tract abnormality

Preliminary screening

- Identify absolute contraindications and modifiable risk factors
- The patient must be educated
- the risks associated with their cause of renal failure
- comorbidities
- operative procedure and risk
- immunosuppression



- Urologic Procedures for evaluation in case of
- UDS in Voiding dysfunction and history of pyelonephritis or reflux
- Cystoscopy in suspected lower urinary tract abnormality
- Retrograde pyelography in suspected upper urinary tract abnormality
- CT scan in suspected renal lesion could not be confirmed by echogram
- Pre-op daily urine amount assessment
- Small bladder capacity due to anuria have possibility to regain normal volume within weeks of transplantation

- High Risk of Perioperative Morbidity or Mortality
- Comorbidity of ESRD increasing risk including CAD, CVA, CHF and DM
- Screened with Cardiac echogram and/or nuclear-medicine cardiac imaging to evaluate myocardial perfusion, ejection fraction, and valvular function
- Poor outcomes in tobacco use
- Any respiratory disease that requires home oxygen is a relative contraindication
- Non-adherence

- Malignancy in Transplant Candidate
- Relative risk for cancer of approximately 1.2 times in ESRD patient
- Disease free waiting period depends on cancer type and risk
- Patients who have low-risk disease felt to be amenable to active surveillance should be considered candidates for transplantation
- Asymptomatic microscopic hematuria should be evaluated according to the American Urological Association (AUA) guidelines (The risk for both kidney and UB cancer is increased with renal failure)
- Complicated renal cysts should be monitored with serial imaging and consider nephrectomy if suspected malignancy and the urine output is limited

- Preservation of residual renal function
- Limit the need for fluid and food restrictions
- Improve the management of hypertension
- Reduce cardiac complications
- Reduce the unnecessary of operative and anesthesia risk for nephrectomy
- Indication for native nephrectomy must be balanced by the risk of observation

- Indications and Timing of Native Nephrectomy
- Symptomatic renal stones could not be cleared by minimal surgery
- Solid renal tumors
- Polycystic kidneys that are symptomatic
- Complicated renal cysts
- Persistent anti-glomerular basement membrane antibody levels
- Significant and uncontrolled proteinuria
- Recurrent pyelonephritis
- High grade VUR with UTI

- Treatment of Bladder Outlet Obstruction
- Medical treatment with α -adrenergic blocking agents and 5α reductase inhibitors
- In some cases will be beneficial of α -blocker in control HTN
- TURP or laser operation in poor medical response
- High risk of BNC or urethral stricture in uremic patient

- Deceased Donor Allocation and Selection
- Patients listed for kidney transplantation
 continues to expand disproportionately to the
 number of kidney transplantations performed

 Currently more than 8,200 patients waiting for deceased-donor kidney transplants, and with about 150 deceased-donor kidney transplantations performed annually



- Inadequate supply of deceased-donor kidneys
- Increased the use of marginal deceased donor kidneys
- Increased the use of living donor kidneys
- Increase in living renal donation
- Minimally invasive donor nephrectomy techniques
- Acceptance of living, biologically unrelated renal donors
- Development of protocols for transplantation across ABO blood group incompatibility

• Current allocation policy is available at the Taiwan Organ Registry and Sharing Center website



人體器官移植條例



絕對因素:血型

• 血型相同或血型相容者。

備註:

- 一、血型相同:器官捐赠者與待移植者之ABO血型一致。
- 二、 血型相容:指符合下列各款之一者:
 - 器官捐贈者血型O型,待移植者血型為A 型、B型或AB型。
 - 器官捐贈者血型A型或B型,待移植者血 型為AB型。

絕對因素:B型肝炎

 器官捐贈者為「B型肝炎表面抗原陽性 (HBsAg(+))」或「B型肝炎表面抗原陰性且 表面抗體陰性且核心抗體陽性(HBsAg(-) and Anti-HBs(-) and Anti-HBc(+))」:僅 能分配予「B型肝炎表面抗原陽性或表面抗 體陽性或核心抗體陽性(HBsAg(+) or Anti-HBs(+) or Anti-HBc(+))」之待移植者。

絕對因素:C型肝炎

 器官損贈者「有C型肝炎(Anti-HCV(+))」: 僅能分配予「有C型肝炎(Anti-HCV(+))且尚 未治癒」之待移植者。

絕對因素:人類免疫缺乏病毒陽性

 器官捐贈者為「人類免疫缺乏病毒陽性 (HIV(+))」:僅能分配予經書面同意之「人 類免疫缺乏病毒陽性(HIV(+))」之待移植 者。

相對因素

- 待移植者之優先順序:人類白血球抗原 (HLA)無錯配「zero ABDR mismatch」且其配偶或三親等以內血 親曾為死後器官捐贈者、人類白血球抗 原(HLA)無錯配「zero ABDR mismatch」、人類白血球抗原(HLA)非 無錯配「non-zero ABDR mismatch」 且其配偶或三親等以內血親曾為死後器 官捐贈者、人類白血球抗原(HLA)非無 錯配「non-zero ABDR mismatch」。
- 辦理器官捐贈者之醫療照護、腦死判 定、必要性檢查與檢驗、協助司法相 驗、器官分配聯繫運送、還體禮儀及資 料登錄通報等事項之醫院。
- 地理位置:器官捐贈者及待移植者所在 區域相同為優先。
- 4. 評分基準:「評分高」優先於「評分低」 之待移植者。
- 5. 評分基準中, 血型相同者加三分。
- 評分相同時,優先順序為「HLA組織抗 原符合配對」之得分高低、「病人年 齡」之得分高低、「等候時間長短」, 最後由移植醫師以「臨床診斷預後最佳 考量」為前提,確認待移植者序位。
 曾為活體肝臟或腎臟器官捐贈者。

備註:

 依左列順序比較。
 依醫療常規,待移植者以接受一枚腎臟 為原則。

- Categories of kidney donors:
 - Standard criteria donor (SCD)
 - Expanded criteria donor (ECD)
 - Donation after circulatory death(DCD)
- The category of donor organs must be decided by the patient and transplant physician


- SCDs are younger than 60 y/o and do not meet any criteria for ECD
- ECD donors
- Age over 60
- Age 50 -59 with >2 risk factors such as death stroke, HTN, or elevated creatinine >1.5 mg/dL
- ECD organs have a 2-year graft survival of 80% versus 88% for an SCD organ
- DCD kidneys
 - Varying lengths of warm ischemia time
 - Susceptible to delayed graft function
 - Long-term graft survival is comparable to SCD kidneys

- Specific consideration such as
- Pediatric donor kidneys may be transplanted en bloc, or, if large enough, split and allocated to two recipients
- Patients with ESRD who have hepatitis C virus (HCV) infection can be transplanted with kidneys from donors who are also HCV positive
- Such recipients should have detectable HCV viral load an no evidence of cirrhosis
- Also consideration in HIV patient

- Histocompatibility
- Human major histocompatibility complex (MHC) is a cluster of more than
 200 genes on chromosome 6p21.31
- Expressed as cell surface proteins on the renal allograft
- Recognized by the recipient's leukocytes and trigger the immune response
- Also serves the important function of protecting the host from pathogens

- Nomenclature of the highly polymorphic HLA antigens
- Class I (HLA-A, HLA-B, and HLA-C)
- HLA class I genes are expressed by all nucleated cells
- Class II (HLADR, HLA-DQ, and HLA-DP)
- HLA class II genes are expressed by antigen-presenting cells (dendritic cells, monocytes, macrophages, and B-lymphocytes) and inflamed tissues (endothelial cells)

- Living donor evaluation
- Medical and urological Hx evaluation
- Renal and urinary tract anatomy evaluation
- Recurrent UTIs
- Nephrolithiasis
- Genitourinary malignancy
- Hematuria
- Congenital disease



- Donor protection consideration
- Excellent health
- No family Hx of HTN, DM, renal disease
- BMI < 30
- Donors younger than 25 years (more years after donation to develop diseases)
- Hyper-filtration injury has not been a significant problem because of endogenous creatinine clearance rapidly approaches 70% to 80% of the preoperative level, and sustained for more than 10 years

- ABO Blood Groups
- Carbohydrate antigens expressed on the surface of red blood cells
- Antibodies will bind to the non-inherited carbohydrate antigens expressed on endothelial cells, leading to activation of the complement cascade, coagulation, thrombosis, and rapid graft loss in ABO incompatible patients
- Certain immunosuppressive medications limit these antibodies in ABO incompatible renal transplants
- The graft endothelial antigen expression downregulated and chronic complement activation is minimal.

- ABO incompatible renal transplants
- -Accetable graft and patient survival in ABO incompatible renal transplants
- Longer term results are not equivalent to blood-type compatible transplants
- Protocols for such transplants varies widely across different programs
- -- Plasmapheresis
- -- IV immunoglobulin (IVIG)
- -- Rituximab
- -- Splenectomy
- -- Require more intensive immunosuppressive regimens

Kidney Recipients Preparation

- Example for recipients in-hospital preparation
- -Sign op and Anesthesia Permit
- -NPO except medicine midnight before op day
- -On and keep IV line
- -Chest PA, KUB, EKG, CBC/DC, PT/APTT
- -Biochemistry (BUN, Cr, AC Sugar, Na, K, Cl, Ca, P, cholesterol, TG), ABO
- & Rh typing p.r.n.
- -RBC Cross matching & Ab Screening for blood transfusion
- -B/T Lymphocyte cross matching PRA (Class I /II)

Kidney Recipients Preparation

- Example for recipients in-hospital preparation (cont.)
- Sodium chloride 0.9% 500ml/BT, ST, IVD
- Cefazolin 1gm/Vial sent to OR, ST, IVD
- Nystatin susp. 100,000U/ml 24ml/BT 3ml ST,PO
- Omeprazole Infusion 40mg/Vial pre-op on call, ST, IVD
- Evaluation of H/D or release PD fluid

Kidney Recipients Preparation

- Example for recipients induction medication and preparation
- Methylprednisolone 1g sent to OR, ST, IVD,
- Simulect 20mg + distilled water 5cc IVD before op
- Tacrolimus 0.15mg/kg/day, in 2 dividing doses or cyclosporin 5mg/kg/day, in 2 dividing doses
- Mycophenolate mofetil 250mg/Cap or Mycophenolate sodium 80mg/Tab, 2~3# BID, PO before op

Summary

- The incidence of ESRD is greater than any urologic malignancy except PCa
- More patients die of ESRD than of any urologic malignancy annually
- Evaluation of ESRD patients for renal transplantation is important to prevent wastage of kidney grafts
- New options are available to allow transplantation with ABO incompatibility and positive cross-matches
- Urologists must be aware of the potential genitourinary problems of transplant recipients